Clinical trial · Interventional
G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients
Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients. Patients all accepted platinum-based chemotherapy 3-4 weeks once per course. The primary end is the incidence of FN in every course of chemotherapy. After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy-induced Neutropenia | — | UNRESOLVED | — |
| Febrile Neutropenia | — | UNRESOLVED | — |
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Myelosuppression Adult | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Long-acting G-CSF | Drug | — | UNRESOLVED |
| Short-acting G-CSF | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Long-acting G-CSF group
- description
- Patients in long-acting G-CSF group accept long-acting with or without short-acting G-CSF.
- interventionNames
- Drug: Long-acting G-CSF
- type
- EXPERIMENTAL
- label
- Short-acting G-CSF group
- description
- Patients in long-acting G-CSF group only accept short-acting G-CSF.
- interventionNames
- Drug: Short-acting G-CSF
Primary outcomes (1)
- measure
- Incidence of febrile neutropenia
- timeFrame
- One year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed primary gynecologic cancer * Good performance status * Aged 18 years or older * Signed an approved informed consents * No immunosuppressive disease Exclusion Criteria: * Not meeting all of the inclusion criteria
References
Publications (1)
- DERIVEDChen X, Wu M, Ma S, Tan X, Zhong S, Li L. Effects of long-acting versus short-acting granulocyte colony stimulating factor after radiotherapy in gynecologic malignancies: a prospective observational cohort study. BMC Cancer. 2024 Dec 18;24(1):1512. doi: 10.1186/s12885-024-13296-1. PMID 39696092